Drugs / BIRT 2584 XX
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT02256813 | Sep → Dec 2005 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02256748 | Jun → Aug 2005 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02256761 | Jan → Jul 2005 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02256878 | Aug 2004 → Nov 2006 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02259894 | Mar → Jun 2004 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00333411 | Jun 2006 → Jun 2008 | psoriasis | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BIRT 2584 XX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02256878 ↗ |
| Action | Inhibit | “BIRT 2584 XX will block the passage of these inflammatory cells from the blood to the skin by blocking LFA-1” NCT00333411 ↗ |
| Route | Oral | “three different doses (100 mg, 300 mg, or 500 mg) of BIRT 2584 XX tablets administered orally once daily” NCT00333411 ↗ |